Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy

Japanese Journal of Clinical Oncology

Volumn 35, Issue 9, 2005, Pages 514-519

  Lin, Yung Chang ^a   Chen, Shin Cheh ^a   Chang, Hsien Kun ^a   Hsueh, Swei ^a   Tsai, Chien Sheng ^a   Lo, Yung Feng ^a   Hwang, Tsann Long ^a   Chen, Miin Fu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adjuvant chemotherapy; Breast cancer; Lymph node metastasis; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 27644454838     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi143     Document Type: Article

References (32)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Cancer Registry Annular Report (1998). Republic of China: Department of Health, The Executive Yuan 2002;48-9.
3. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975; 292:117-22.
4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
5. Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna G. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001;28:13-29.
6. Hortobagyi GN. Adjuvant systemic therapy for early breast cancer: progress and controversies. Clin Cancer Res 2001;7:1839-42.
7. Saze RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol 1989;5:102-7.
8. Early Breast Cancer Trials Cooperative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998;352:930-42.
9. Hunchins L, Green S, Ravidin R, Lew D, Martino S, Abelogg M, et al. CMF versus CAF with and without Tamoxifen in high-risk node negative breast cancer patients and a natural history follow-up study in low-risk node negative patients: First Result of Intergroup Trials INT 0102. Proc Am Soc Clin Oncol 1998;17:1A (Abstract 2).
10. Piccart MF, Di Leo A, Beaudoin M, Vindevoghel A, Michel J, Focan C, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-10.
11. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Chemotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Results from NSABP B23. J Clin Oncol 2001;19:931-42.
12. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-8.
13. Mouridsen HT, Andersen J, Anderson M, Domobernowsky P, Ejlertsen B, Rose C, et al. Adjuvant anthracycline in breast cancer: Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999;18: 68a (Abstract 254).
14. Lin YC, Chen SC, Chang HK, Hsueh S, Hwang TL. Prognostic factors of breast cancer patients with 1 to 3 lymph node metastases after adjuvant chemotherapy. Euro J Cancer 2001;37(Suppl 6): 183 (abstract 667).
15. Chen SC, Chen MF, Hwang TL, Chao TC, Lo YF, Hsueh S, et al. Prediction of supraclavicular lymph node metastasis in breast carcinoma. Int J Radiat Oncol Biol Phys 2002;52:614-9.
16. Goldhirsch A, Glick JH, Geller RD, Costes AS, Senn HJ. Meeting highlight: International Consensus Panels on the Treatment of Primary Breast Cancer-Seventh International Conference on Adjuvant Chemotherapy of Primary Breast Cancer. J Clin Oncol 2001;19:3817-27.
17. Tan AR, Swain SM. Adjuvant chemotherapy for breast cancer: An update. Semin Oncol 2001;28:359-76.
18. National Institute of Health Consensus Development Conference. J Natl Cancer Inst Monogr 2001;30:1-30.
19. Chembers SK, Chopky RL, Chambers JT, Schwartz PE, Duffy TP. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 1989;64:2459-61.
20. von Hoff DD, Rozencweig M, Piccart MJ. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23-33.
21. Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37-43.
22. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of respectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991;9:1124-30.
23. French Adjuvant Study Group. Benefit of a high-dose eiprubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognosis factors: 5-year follow-up results of French Adjuvant study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
24. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
25. Fisher B, Slack NH, Bross IDJ. Cancer of the breast: Size of neoplasm and prognosis. Cancer 1969;24:1071-80.
26. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-positive breast cancer: The curability of small cancers with a limited number of positive nodes. J Clin Oncol 1996;14:3105-11.
27. Rakowsky E, Klein B, Kahan E, Derazne E, Lurie H. Prognostic factors in node-positive operable breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 1992;21:121-31.
28. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base reports on breast carcinoma characteristics and outcome in relation to age. Cancer 1996;78:1838-43.
29. Swanson GM, Lin C-S. Survival patterns among younger women with breast cancer: The effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994;16:69-77.
30. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, et al. Is chemotherapy alone adequate for young women with estrogen-receptor-positive breast cancer? Lancet 2000; 355:1869-74.
31. Cheng SH, Tsou MH, Liu MC, Jian JJ, Cheng JC, Leo SY, et al. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000; 63: 213-23.
32. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;7:1049-56.